121 – 130 of 382
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Combination of pegylated IFN-alpha 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- Contribution to journal › Article
-
Mark
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B
- Contribution to journal › Article
-
Mark
IL-7 mediates Ebf-1-dependent lineage restriction in early lymphoid progenitors
- Contribution to journal › Article
-
Mark
Secondary autoimmune diseases occurring after HSCT for an autoimmune disease: a retrospective study of the EBMT Autoimmune Disease Working Party
- Contribution to journal › Article
-
Mark
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)
- Contribution to journal › Article
-
Mark
Activated protein C cofactor function of protein S: a novel role for a gamma-carboxyglutamic acid residue
- Contribution to journal › Article
-
Mark
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study
- Contribution to journal › Article
-
Mark
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- Contribution to journal › Article
-
Mark
Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.
- Contribution to journal › Article
-
Mark
A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q
- Contribution to journal › Article
